Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

Arcutis Biotherapeutics Inc (ARQT)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Arcutis's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
27.73 -0.39    -1.39%
14:55:01 - Real-time Cboe. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
ISIN:  US03969K1088 
CUSIP:  03969K108
  • Volume: 86,209
  • Bid/Ask: 27.69 / 27.79
  • Day's Range: 27.31 - 28.12
Arcutis 27.73 -0.39 -1.39%
IndustryBiotechnology & Drugs
SectorHealthcare
Employees

54

Equity Type

ORD

Arcutis Biotherapeutics Inc is a United States-based biopharmaceutical company. The Company focuses on developing treatments for unmet needs in immune-mediated dermatological diseases or immune-dermatology. Its strategy is to identify and develop treatments against validated biological targets in dermatology that deliver a differentiated clinical profile that addresses shortcomings of existing therapies in targeted indications.

Contact Information

Phone +1-805-4185006
Fax 302-5313150

Top Executives

Name Age Since Title
Todd Franklin Watanabe 53 2017 President, Chief Executive Officer, Director
Scott L. Burrows 44 2021 Chief Financial Officer, Principal Accounting Officer
Kenneth A. Lock 47 2019 Chief Commercial Officer
David W. Osborne 60 2017 Co-Founder, Chief Technical Officer
Heather Rowe Armstrong - 2020 Vice President of Investor Relations and Corporate Communications
Kimberly Lathroum - 2020 Vice President of Marketing
Halley E. Gilbert 51 2020 Director
Jay Ramsinghani - 2020 Vice President of Commercial Strategy and Operations
Ayisha Jeter - 2020 Vice President of Market Access
Howard G. Welgus 69 2020 Director
Patricia A. Turney 54 2020 Senior Vice President - Operations
David Berk 41 2019 Vice President - Clinical Development
Meg Elias 54 2019 Vice President - Clinical Operations
Keith L. Klein 56 2019 General Counsel
Charlotte Merritt 57 2018 Vice President - Regulatory Affairs
Frank Pompilio 56 2019 Vice President - Medical Affairs
Patrick J. Heron 50 2019 Independent Chairman of the Board
Bhaskar Chaudhuri 66 2016 Independent Director
Ricky Sun 47 2018 Independent Director
Joseph L. Turner 69 2020 Independent Director
Patrick Burnett 49 2020 Chief Medical Officer
Bethany Dudek - 2020 Vice President - Quality
Terrie J. Curran 52 2020 Director
Matthew R. Moore 48 2021 Senior Vice President, Chief Business Officer
Courtney Barton - 2021 Chief Compliance Officer, Vice President, Chief of Staff
Rajvir Madan - 2021 Chief Digital and Information Officer
Sue-Jean Lin - 2021 Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ARQT Comments

Write your thoughts about Arcutis Biotherapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email